The anti-angiogenic capability of SF was observed by CD31 staining, in which VP and SF-treated tumors had significantly less intra-tumor vasculature, as well as by downregulation of vascular endothelial growth factor A (VEGF-A) gene expression (Fig. 1h, i). This evidence concerns the gene VEGFA and neoplasm.